AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
RegulatoryapprovedTEPKINLYLenalidomideRituximabPositive
AI Analysis
Summary
AbbVie announced European Commission approval of TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma in the second-line setting, marking the first bispecific-based therapy approved in Europe for this indication and offering a chemotherapy-free treatment option.
Clinical Trial Data
Phase
Phase 3
Outcome Details
European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma in the second-line setting
Importance:8/10
Sentiment:
0.90
regulatory approvalEuropean Commissiononcologybispecific antibodyfollicular lymphomacombination therapychemotherapy-free
Related Companies
Read the original article
Published by PR Newswire Pharma on July 6, 2026 5:45 PM